Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment (CodeBreaK201)

The main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in participants who receive sotorasib at either 960 mg daily or 240 mg daily whose tumors are programmed death-ligand 1 (PD-L1) Tumor Proportion Score …

brain metastases
measurable disease
STK11
LKB1
KRAS
  • 0 views
  • 30 Jun, 2022
  • 57 locations
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

resected Stage IIB-IIIB (early-stage) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC

lung carcinoma
atezolizumab
adjuvant chemotherapy
cancer chemotherapy
chemoradiotherapy
  • 1 views
  • 13 Jun, 2022
  • 31 locations
A Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (ARTEMIDE-01)

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody, AZD2936 is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

lung carcinoma
  • 0 views
  • 27 Apr, 2022
  • 9 locations
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

stereotactic body radiation therapy (SBRT) and low dose radiotherapy (LDRT) in treating patients with stage IV non-small cell lung cancer (NSCLC). At least 39 participants will be enrolled in this study

monoclonal antibodies
cancer
pd-l1
measurable disease
  • 0 views
  • 16 Feb, 2022
  • 1 location
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

While cigarette smoking remains the primary cause of most lung cancer cases, lung carcinoma in never smokers account for nearly 20 percent of cases. Never smokers with lung cancer typically present with different molecular profiles from that of smokers, which results in prognostic and therapeutic implications. Molecular changes in NSCLC …

  • 0 views
  • 23 Mar, 2022
  • 1 location
Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC

, partly as an abscopal effect, and thereby improving quality of life and possible also prolonging survival for stage IV NSCLC.

lung carcinoma
metastasis
lung cancer
cancer chemotherapy
brain metastases
  • 0 views
  • 24 Jan, 2021
  • 3 locations
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

throughout the body) in treating patients with stage IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and

neutrophil count
stereotactic radiation
chemoradiotherapy
stereotactic body radiation
cancer
  • 0 views
  • 05 Jun, 2022
  • 1 location
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV. Comprehensive genomic analysis may identify specific gene mutations (changes in deoxyribonucleic acid [DNA]) and help doctors to tailor treatment to target the specific mutations.

systemic therapy
neutrophil count
recurrent non-small cell lung cancer
metastasis
biomarker analysis
  • 2 views
  • 19 Apr, 2022
  • 3 locations
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

This phase I/II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating participants with stage IV non-small cell lung cancer or that has

measurable disease
monoclonal antibodies
liver metastasis
selumetinib
gilbert's syndrome
  • 8 views
  • 06 Feb, 2022
  • 1 location
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

pembrolizumab, and to see how well they work in treating patients with stage IV non-small cell lung cancer. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill

lung carcinoma
alectinib
pembrolizumab
measurable disease
neutrophil count
  • 0 views
  • 17 Feb, 2022
  • 1 location